FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

A Pilot Study for the Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) Pulsed With Human Papillomavirus Type 16 E7 Antigen

This study is currently Recruiting

June 2002 By National Taiwan University Hospital

First Recieved on September 9, 2005

Last Updated on December 19, 2005

Sponsor: National Taiwan University Hospital
Collaborators:
Information provided by: National Taiwan University Hospital
Identifier: NCT00155766

Purpose

Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-based chemotherapy. After failure of the cisplatin-based chemotherapy, there is still no treatment that has been proved to be effective. Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16,18,31,45) have been strongly associated with cervical cancer. HPV 16 was found in more than 50% of cervical cancer tissues. Results from many animal tumor models have indicated that immunization with tumor antigen-pulsed dendritic cells can trigger a long-lasting anti-tumor immune response and significantly inhibit the growth of implanted tumor cells. Recently, many clinical trials have been conducted to evaluate the feasibility and safety of immunizing cancer patients with tumor antigen-pulsed dendritic cells. No severe toxicity has been reported and some patients were shown to respond to the treatment. Based on previous animal and clinical studies by other investigators, we propose to evaluate the potential of immunizing cancer patients with antigen-pulsed autologous dendritic cells as a cancer vaccine to treat for recurrent cervical cancers after failure of cisplatin-based chemotherapy treatment or refusing chemotherapy. In this study, we will generate dendritic cells by culturing patient's autologous PBMC with GM-CSF and IL-4 in vitro. These dendritic cells will be pulsed with synthetic peptides representing the CTL epitopes on HPV Type 16 E7. Antigen-pulsed dendritic cells will be injected into inguinal lymph nodes under the guidance of real-time sonography. Each patient will receive four injections and 12 patients in total will be recruited for this study.

Study Type: Interventional
Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Eligibility

Ages Eligible for Study:18 Years
Genders Eligible for Study:Female
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: 1. recurrent cervical cancer 2. HPV 16 infection 3. Previously received cisplatin ot 5-FU based chemotherapy or refused to receive chemotherapy 4. HLA-A2 haplotype 5. Older than 20 years old 6. ECOG I or II 7. Life expectancy longer than 3 months 8. Adequate bone marrow reserve 9. pregnancy test: negative 10. Informed consent obtained Exclusion Criteria: 1. CNS metastasis 2. Acute or chronic infection 3. Pregnant or lactating women 4. Asthma 5. Cardiac diseases such as heart failure, unstable angina, arrhythmia, myocardial infarction 6. Autoimmune disease 7. Previously other cancers (except basal cell cancer) 8. Without chemotherapy, biotherapy for more than 6 weeks

Investigators

  • Investigator: Chi-An Chen, MD - Principal Investigator - National Taiwan University Hospital

Locations

  • National Taiwan University Hospital

    Taipei, Taiwan

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.